Conference
September 13, 2021

The Top 100 Oncology Conferences for 2021

Conference
May 17, 2021

The Top 100 Oncology Conferences for 2021

Author

In 2020, there were more than 1,350 medical conferences in the United States alone, and 447 of them focused on oncology.  

With more events popping up in every corner of the world, and the option to attend virtually for many, how can you develop the best conference calendar for what remains of 2021?  

Our team of experts put together a list of the top 100 oncology conferences happening in 2021, organized in an easy-to-reference calendar view.

Download the 2021 List

We’ve done even more analysis to identify the top 5 events. Our ranking criteria considered the focus of the conference, the number of abstracts expected, and the attendance of past meetings.  

Once you’ve identified your own Top 10,  LARVOL can help you maximize your attendance.  

LARVOL CONF: Your Oncology Conference Planning Solution

LARVOL CONF planners will bring you the information you need when you need it! Our analysts review and manually curate each conference’s abstracts and titles as soon as they’re released and deliver a straightforward spreadsheet tool outlining all sessions, abstracts, identified diseases, products, and mechanisms of action (MOAs).

With the CONF planner, you’ll get the latest facts at each stage of the conference:

  • Preliminary Program Release
  • Titles Release
  • Abstract Release
  • Late-Breaking Abstracts
  • Post-Conference Twitter activity

Download our conference list here and click here to request your LARVOL CONF planner.  

Expert Insights on Oncology Conference Abstracts

In addition to planning ahead for upcoming conferences, it's also important to reflect on the data presented and it's impact on the standard-of-care. LARVOL hosts live, 30-minute panel interviews immediately following major oncology conferences. These panels consist of key opinion leaders (KOLs) and experts in the cancer type at hand discussing 2-3 abstracts, moderated by a LARVOL expert in cancer research.

These conversations present a unique opportunity to further the scientific discussion around new scientific data and are a valuable source of insight into the opinions of experts on the treatments covered in the abstracts.

LARVOL Panel Series are planned for the following oncology conferences in 2021:

  • AACR
  • ASCO
  • IASLC WCLC
  • ESMO
  • SABCS
  • ASH

Contact us for more information on these events and download your list of the top 100 oncology conferences for 2021!

To request a demo of VIEW visit here.

Download attached file
Not rated
Allison Betof Warner, MD, PhD (she/her) 4
3743
Manhattan, NY
November 10, 2022

79% had reduction in disease. ORR 31%. Many responses deepen over time.

Not rated
Allison Betof Warner, MD, PhD (she/her) 3
3743
Manhattan, NY
November 10, 2022

Median DOR not yet reached. Median OS 13.9 mo. 12 mo OS was 54%. As typical with immunotherapy, we see a nice tail on the curve. #TIL#SITC22

Positive
Alex Shoushtari, MD
2253
New York, USA
November 10, 2022

Important work on efficacy of TIL therapy lifileucel in PD-1 resistant #melanoma being presented at #SITC22. Pretty good durability for this heavy lift of a treatment.

Not rated
Allison Betof Warner, MD, PhD (she/her) 2
3743
Manhattan, NY
November 10, 2022

Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.

Positive
Hussein Tawbi, MD, PhD
1685
Houston, TX
November 10, 2022

Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated

Positive
Allison Betof Warner, MD, PhD (she/her) 1
3744
Manhattan, NY
November 10, 2022

Where does this leave us with #TIL therapy for #melanoma? IMO, this response rate/durability justifies accelerated approval. Pts with PD-1 refractory melanoma need options. It’s FAR from a perfect tx but provides meaningful clinical benefit. What say you melanoma Twitterverse?

Not Rated
Sumanta K. Pal, MD, FASCO
15083 Followers
Los Angeles, CA
November 8, 2022

Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A

not rated
Shilpa Gupta
5095 Followers
Cleveland, OH
November 8, 2022
Not Rated
Tian Zhang, MD, MHS
6463 Followers
Dallas, TX
November 8, 2022

CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe

Not Rated
Moshe Ornstein MD
1930 Followers
Cleveland, OH
November 8, 2022

Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt

Not Rated
Shuchi Gulati MD
12476 Followers
Seattle, WA
November 8, 2022

Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7

Not Rated
Petros Grivas
12476 Followers
Seattle, WA
November 8, 2022

Subscribe to our newsletter

Sign up for our newsletter to get the latest news, updates and high-impact data delivered directly to your inbox.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.